Financial Summary (All financials)
| In millions, except per share items | Dec-31-22 | Dec-31-21 | Dec-31-20 | Dec-31-19 |
| Revenues | 8.4 | 2.6 | 1.3 | 0.2 |
| Revenue growth | 227.2% | 92.1% | 491.2% | |
| Cost of goods sold | 11.8 | 8.0 | 5.8 | 0.7 |
| Gross profit | -3.4 | -5.4 | -4.4 | -0.5 |
| Gross margin | -40.3% | -211.5% | -331.5% | -199.1% |
| Sales and marketing | 20.6 | 22.9 | 7.0 | 6.6 |
| Research and development | 33.9 | 26.3 | 7.7 | 10.2 |
| General and administrative | 62.1 | 104.1 | 10.2 | 8.6 |
| EBIT | -119.9 | -158.8 | -29.3 | -28.9 |
| EBIT margin | -1428.6% | -6186.9% | -2194.9% | -12803.5% |
| Pre-tax income | -158.8 | -217.4 | -60.3 | -29.0 |
| Income taxes | 0.4 | 0.4 | 0.0 | 0.0 |
| Tax rate | | | 0.0% | 0.0% |
| Net income | -159.3 | -217.8 | -60.3 | -29.0 |
| Net margin | -1896.8% | -8487.1% | -4511.8% | -12842.5% |
| |
| Diluted EPS | ($1.58) | ($5.00) | ($1.66) | ($2.56) |
| Shares outstanding (diluted) | 100.8 | 43.6 | 36.3 | 11.3 |
| |
| EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |
|